https://www.selleckchem.com/pr....oducts/acalabrutinib
6%). All cases occurred during therapy with anti-TNF agents [14/23 (61%) patients were treated with adalimumab and 9/23 (39%) patients were treated with infliximab]. The therapeutic approach directed at maintaining/holding the undergoing biologic therapy is still uncertain. Further studies are needed to determine the most appropriate treatment choice toward ongoing biologic therapy. End-stage liver disease is a global public health problem with a high mortality rate. Early identification of people at risk of poor prognosis is fund
Like
Comment
Share
